Medtronic (NYSE:MDT) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Medtronic (NYSE:MDT) from a buy rating to a hold rating in a report issued on Sunday morning.

Other equities research analysts have also recently issued research reports about the stock. UBS Group reiterated a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Barclays reiterated an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. TD Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Mizuho upgraded Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Daiwa Securities Group reduced their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Trading Up 0.6%

Shares of Medtronic stock opened at $97.60 on Friday. Medtronic has a 1 year low of $79.55 and a 1 year high of $106.33. The company’s fifty day simple moving average is $98.93 and its 200-day simple moving average is $96.92. The company has a market cap of $125.31 billion, a price-to-earnings ratio of 27.19, a PEG ratio of 2.45 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is 79.11%.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of MDT. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter worth about $27,000. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the 4th quarter valued at about $27,000. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic in the second quarter worth approximately $27,000. Lodestone Wealth Management LLC purchased a new position in shares of Medtronic during the fourth quarter valued at approximately $27,000. Finally, Anfield Capital Management LLC lifted its position in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).